PLx Pharma Receives Multiple Grants From National Institutes of Health

PLx Pharma claimed that the other grants NIH has awarded to it in the recent months include The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Plx Pharma $798,642 to support development of PL3100 Naproxen as a treatment for arthritis and chronic pain.

The Eunice Kennedy Shriver National Institute of Child Health & Human Development awarded PLx Pharma $157,934 to support development of PL4500 Indomethacin IV for use in preterm neonates for use in the treatment of patent ductus arteriosus while reducing the risk of developing necrotising enterocolitis, a devastating digestive disease afflicting low birth weight newborns.

National Institute of Diabetes and Digestive and Kidney Diseases awarded $992,972 to Lichtenberger and colleagues at the University of Texas Health Science Center to evaluate the mechanism of action of multiple PLx Pharma products in development and awarded PLx Pharma $37,500 as a supplement for continuation of an existing grant.

Lenard Lichtenberger, chief science officer of PLx Pharma and, co-founder and professor at the University of Texas Health Science Center at Houston, said: “We appreciate the continuing support of the NIH in the development of GI safer NSAIDs, which has proven beneficial in the validation of our approach.

“I am excited that our technology is now in human trials and demonstrating enhanced GI safety as evidenced by our recently announced PL2200 Aspirin clinical results.”